Towards Even More Reduced Trauma in the Non-Medical Therapy of Benign Uterine Wall Disease? Volume 4 - Issue 5

De Wilde RL¹, Devassy R¹, Verhoeven HC¹, Becker S², Krentel H¹ and Torres de la Roche LA¹

• ¹University Hospital for Gynecology, Carl von Ossietzky University, Oldenburg, Germany
• ²Department of Obstetrics and Gynecology, Johannes-Gutenberg-University, Frankfurt, Germany

Received:November 8, 2021Published: November 17, 2021

Corresponding author: De Wilde RL, University Hospital for Gynecology, Carl von Ossietzky University, Oldenburg, Germany

DOI: 10.32474/IGWHC.2021.05.000201

Fulletxt PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Minimal-access therapy in symptomatic myomata and adenomyosis has proved to be gold standard in the surgical management [1]. Pure medical treatment showed to be effective on a short or middle term time frame but influences hormonal homeostasis or even potentially provokes severe adverse effects [2]; thereby it couldn’t succeed to become the treatment of choice. In the last decades, we could see an evolution in the surgical cancer therapy, from ultraradical surgery with laparotomy, to minimalinvasive techniques as way of entrance, now proceeding to tailored operations with concomitant chemo- or immunotherapy. This individualized concept also seems to be adaptable to the treatment of benign uterine wall diseases. Coming from laparotomy with eventually hysterectomy, reducing the impact on body image by minimal-access myomectomy, newer even less traumatizing possibilities are emerging. Besides the uterine artery embolization, bearing the risk of a major uterine necrosis, a more selective nonsurgical therapy has emerged.

Editorial| References|